Conclusion
In this review, we demonstrated that in critically ill patients enteral
immunomodulatory diet might be benefitial compared to standard formula
specially in septic and ARDS conditions. However, the long-term benefits
of this diet on clinical outcomes and mortality needs to be tested in
well-designed trials with longer follow-up.